Form 4: Travere Therapeutics SVP, Chief Accounting Officer, Sandra Calvin, Reports Transactions

Sandra Calvin, SVP, Chief Accounting Officer of Travere Therapeutics, reports acquisition of 13,000 shares and sale of 3,348 shares to cover tax obligations.

Summary

• On January 31, 2025, Sandra Calvin, SVP, Chief Accounting Officer of Travere Therapeutics, acquired 13,000 shares of common stock.
• These shares were acquired at a price of $0.
• Following this transaction, Calvin directly owns 67,002 shares of common stock.
• On February 3, 2025, Calvin sold 3,348 shares of common stock at $20.12 per share.
• This sale was to cover tax withholding obligations related to the settlement of vested restricted stock units.
• Following this transaction, Calvin directly owns 63,654 shares of common stock.
• On January 31, 2025, Calvin acquired an option to buy 26,000 shares of common stock at an exercise price of $20.46, expiring on January 31, 2035.
• One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing, reflecting routine transactions. It doesn't inherently convey positive or negative sentiment.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of stock transactions by a company insider, as required by the SEC. It provides transparency into the trading activities of key personnel.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership by a company insider.
• Employees may be interested in the details of stock option grants and vesting schedules.

Key Dates

Keywords

Form 4, Beneficial Ownership, Travere Therapeutics, TVTX, Sandra Calvin, Stock Options, Restricted Stock Units, Tax Withholding